Halozyme Therapeutics | HALO - Current Assets


Halozyme Therapeutics reported $825.21M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.06B 14.31M Dec/2025
Agios Pharmaceuticals USD 942.05M 91.06M Dec/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
Amarin USD 628.33M 21.52M Sep/2025
Amgen USD 29.06B 1.17B Dec/2025
Baxter International USD 6.87B 61M Dec/2025
Cara Therapeutics USD 43.13M 4.18M Jun/2025
Cytokinetics USD 916.97M 60.37M Dec/2025
DBV Technologies USD 88.88M 32.36M Sep/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Esperion Therapeutics USD 462.57M 102.11M Dec/2025
Halozyme Therapeutics USD 825.21M 503.54M Dec/2025
Intrexon USD 23.72M 45.04M Jun/2024
Ionis Pharmaceuticals USD 2.99B 471.01M Dec/2025
MannKind USD 291.58M 67.26M Dec/2025
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Nektar Therapeutics USD 281.36M 94.79M Sep/2025
Pfizer USD 46.92B 3.22B Sep/2025
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
United Therapeutics USD 3.7B 208.5M Dec/2025
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025